Yuanbao (NASDAQ:YB) Issues Earnings Results

Yuanbao (NASDAQ:YB) issued its quarterly earnings results on Wednesday. The company reported $0.99 EPS for the quarter, FiscalAI reports. The company had revenue of $167.98 million during the quarter.

Here are the key takeaways from Yuanbao’s conference call:

• Strong Q4 and full‑year 2025 financial results — Q4 revenue of RMB 1.18 billion (+32.2% YoY), full‑year revenue RMB 4.37 billion (+33.1%), full‑year net income RMB 1.31 billion (+51%) and year‑end cash of RMB 4.04 billion, with net margin improving to 29.9%.
• Management attributes growth to its AI and data platform — over 4,900 models (analyzing >5,700 labels), an AI team >10% of headcount, and AI‑driven support across pre‑sales, post‑sales and claims that helped new policy volumes rise ~36.7% YoY to ~30.66 million.
• Favorable policy backdrop — government initiatives (e.g., Commercial Insurance Innovative Drug Catalog, 2026 work priorities) are seen as catalysts for commercial health insurance demand, and the company has already broadened drug coverage in its higher‑end medical products.
• Expenses rising — selling & marketing spending increased materially (Q4 S&M +47.7% to RMB 552.3m; FY S&M RMB 2.22b) and R&D rose 58% to RMB 365.1m, which could weigh on operating leverage if revenue growth moderates.
• Shareholder returns — management says it is “evaluating” dividend/capital return options but provided no specific dividend timeline, leaving near‑term payout policy uncertain.

Yuanbao Trading Down 2.0%

Shares of YB opened at $19.09 on Thursday. The firm’s fifty day simple moving average is $19.95 and its two-hundred day simple moving average is $20.97. Yuanbao has a 12 month low of $14.04 and a 12 month high of $31.00. The stock has a market capitalization of $860.58 million and a P/E ratio of 6.77.

Institutional Investors Weigh In On Yuanbao

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC grew its stake in shares of Yuanbao by 68.7% in the 4th quarter. Barclays PLC now owns 41,988 shares of the company’s stock worth $851,000 after acquiring an additional 17,105 shares in the last quarter. Franchise GP Ltd bought a new stake in Yuanbao in the 4th quarter worth about $1,351,000. JPMorgan Chase & Co. increased its stake in Yuanbao by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,226 shares of the company’s stock valued at $653,000 after buying an additional 11,607 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Yuanbao during the 3rd quarter worth approximately $59,613,000. Finally, WFM ASIA BVI Ltd boosted its holdings in Yuanbao by 89.9% in the 3rd quarter. WFM ASIA BVI Ltd now owns 182,500 shares of the company’s stock worth $3,584,000 after buying an additional 86,414 shares during the period.

Wall Street Analyst Weigh In

Several research firms recently weighed in on YB. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Yuanbao in a research note on Monday, December 29th. Citigroup initiated coverage on shares of Yuanbao in a report on Monday, February 23rd. They set a “neutral” rating and a $21.80 price target for the company. Finally, Wall Street Zen downgraded Yuanbao from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Yuanbao presently has a consensus rating of “Hold” and a consensus target price of $21.80.

About Yuanbao

Our mission is to protect health and well-being through technology. We are a leading technology-driven online insurance distributor in China. We take pride in pioneering the seamless integration of insurance with cutting-edge technologies, and have constructed a highly efficient full consumer service cycle engine. Through this engine, we successfully distribute suitable and high-quality insurance products to over ten million insurance consumers. According to Frost & Sullivan, we were the largest independent insurance distributor in China’s personal life and accident & health (A&H) insurance market in terms of first year premiums in 2023.